World Health Organization recommendations on the treatment of drug-resistant tuberculosis, 2020 update
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Antimicrobial resistance is a major public health problem globally. Likewise, forms of tuberculosis (TB) resistant to first- and second-line TB medicines present a major challenge for patients, healthcare workers and healthcare services. In November 2019, the World Health Organization (WHO) convened an independent international expert panel to review new evidence on the treatment of multidrug- (MDR) and rifampicin-resistant (RR) TB, using the Grading of Recommendations Assessment, Development and Evaluation approach. Updated WHO guidelines emerging from this review, published in June 2020, recommend a shorter treatment regimen for patients with MDR/RR-TB not resistant to fluoroquinolones (of 9–11 months), with the inclusion of bedaquiline instead of an injectable agent, making the regimen all oral. For patients with MDR-TB and additional fluoroquinolone resistance, a regimen composed of bedaquiline, pretomanid and linezolid may be used under operational research conditions (6–9 months). Depending on the drug-resistance profile, extent of TB disease or disease severity, a longer (18–20 months) all-oral, individualised treatment regimen may be used. In addition, the review of new data in 2019 allowed the WHO to conclude that there are no major safety concerns on the use of bedaquiline for >6 months’ duration, the use of delamanid and bedaquiline together and the use of bedaquiline during pregnancy, although formal recommendations were not made on these topics. The 2020 revision has highlighted the ongoing need for high-quality evidence and has reiterated the need for clinical trials and other research studies to contribute to the development of evidence-based policy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A new tuberculosis treatment regimen for drug-resistant tuberculosis, endorsed by WHO, that is efficacious, safe, and shorter than previous regimens could have a role in reducing tuberculosis deaths.51”
From Global, regional, and national age-specific progress towards the 2020 milestones of the WHO End TB Strategy: a systematic analysis for the Global Burden of Disease Study 2021 (2024) · cites this paper as [51]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
Guyatt, G. H., Oxman, A. D., Vist, G. E., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39489.470347.ad · Cited by 23,305
What is ‘quality of evidence’ and why is it important to clinicians?
Guyatt, G. H., Oxman, A. D., Kunz, R., Vist, G. E., Falck-Ytter, Y., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39490.551019.be · Cited by 3,250
Sustainable Development Goals: Law, Theory and Implementation
(2018) · Edward Elgar Publishing eBooks · doi:10.4337/9781786438768 · Cited by 1,925
The World Health Organization Global Action Plan for antimicrobial resistance
Mendelson, M., & Matsoso, M. P. (2015) · South African Medical Journal · doi:10.7196/samj.9644 · Cited by 1,155
Uplekar, M., Weil, D., Lonnroth, K., Jaramillo, E., Lienhardt, C., Dias, H. M., Falzon, D., Floyd, K., Gargioni, G., Getahun, H., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60570-0 · Cited by 1,117
Self-citationTreatment of Highly Drug-Resistant Pulmonary Tuberculosis
Conradie, F., Diacon, A. H., Ngubane, N., Howell, P., Everitt, D., Crook, A. M., Mendel, C. M., Egizi, E., Moreira, J., Timm, J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1901814 · Cited by 1,044
Short, Highly Effective, and Inexpensive Standardized Treatment of Multidrug-resistant Tuberculosis
Van Deun, A., Maug, A. K. J., Salim, M. A. H., Das, P. K., Sarker, M. R., Daru, P., & Rieder, H. L. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201001-0077oc · Cited by 647
Ahmad, N., Ahuja, S. D., Akkerman, O. W., Alffenaar, J.-W. C., Anderson, L. F., Baghaei, P., Bang, D., Barry, P. M., Bastos, M. L., Behera, D., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31644-1 · Cited by 632
Self-citationFinancial burden for tuberculosis patients in low- and middle-income countries: a systematic review
Tanimura, T., Jaramillo, E., Weil, D., Raviglione, M., & Lönnroth, K. (2014) · European Respiratory Journal · doi:10.1183/09031936.00193413 · Cited by 586
Self-citationTreatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline
Nahid, P., Mase, S. R., Migliori, G. B., Sotgiu, G., Bothamley, G. H., Brozek, J. L., Cattamanchi, A., Cegielski, J. P., Chen, L., Daley, C. L., et al. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201909-1874st · Cited by 462
Research works printed but not linked: 1
- Dooley K , Rosenkranz S , Conradie F , et al. QT effects of bedaquiline, delamanid or both in MDR-TB patients: the DELIBERATE trial. Conference on Retroviruses and Opportunistic Infections (CROI). Washington, USA. March 4–7, 2019. Available from: https://www.croiconference.org/abstract/qt-effects-bedaquiline-delamanid-or-both-mdr-tb-patients-deliberate-trial/
Cited by
Items 201–300 of 302
Panisello, F. A., Febrer, B. S., Cordón, A. M. I. L., López, N. R. G., García, E. M., & Soriano‐Arandes, A. (2022) · Archivos de Bronconeumología · doi:10.1016/j.arbres.2022.11.013
Kootery, K. P., & Sarojini, S. (2022) · Research Square · doi:10.21203/rs.3.rs-2307474/v1
Kootery, K. P., & Sarojini, S. (2023) · Research Square · doi:10.21203/rs.3.rs-2307474/v2
Treatment outcome of patients with co-existing TB and LC: systematic reviews and meta-analysisPreprint
Zhang, H., li, W.-J., Chen, Y., chai, Y.-Q., Zhao, Y., & Gu, X. (2023) · Research Square · doi:10.21203/rs.3.rs-2538089/v1
Criminal Justice Issues and the COVID-19 Pandemic
Bennett, B., Freckelton, I. R., & Wolf, G. (2023) · Oxford University Press eBooks · doi:10.1093/oso/9780192896742.003.0008
Litigation and Legal Challenges to Emergency Orders
Bennett, B., Freckelton, I. R., & Wolf, G. (2023) · Oxford University Press eBooks · doi:10.1093/oso/9780192896742.003.0006
Production, Regulation, and Distribution of COVID-19 Treatments and Vaccines
Bennett, B., Freckelton, I. R., & Wolf, G. (2023) · Oxford University Press eBooks · doi:10.1093/oso/9780192896742.003.0012
Gostin, L. O. (2023) · Oxford University Press eBooks · doi:10.1093/oso/9780192896742.002.0006
Risk, Impact, and Disadvantage
Bennett, B., Freckelton, I. R., & Wolf, G. (2023) · Oxford University Press eBooks · doi:10.1093/oso/9780192896742.003.0007
Bennett, B., Freckelton, I. R., & Wolf, G. (2023) · Oxford University Press eBooks · doi:10.1093/oso/9780192896742.003.0001
Bennett, B., Freckelton, I. R., & Wolf, G. (2023) · Oxford University Press eBooks · doi:10.1093/oso/9780192896742.002.0008
Bennett, B., Freckelton, I. R., & Wolf, G. (2023) · Oxford University Press eBooks · doi:10.1093/oso/9780192896742.002.0009
Past Legal and Regulatory Responses to Infectious Diseases
Bennett, B., Freckelton, I. R., & Wolf, G. (2023) · Oxford University Press eBooks · doi:10.1093/oso/9780192896742.003.0002
Domestic Laws and Emergency Measures
Bennett, B., Freckelton, I. R., & Wolf, G. (2023) · Oxford University Press eBooks · doi:10.1093/oso/9780192896742.003.0005
Law, Regulation, and Rights: Reflections on the COVID-19 Pandemic
Bennett, B., Freckelton, I. R., & Wolf, G. (2023) · Oxford University Press eBooks · doi:10.1093/oso/9780192896742.003.0013
Bennett, B., Freckelton, I. R., & Wolf, G. (2023) · Oxford University Press eBooks · doi:10.1093/oso/9780192896742.002.0011
Bennett, B., Freckelton, I. R., & Wolf, G. (2023) · Oxford University Press eBooks · doi:10.1093/oso/9780192896742.003.0003
Bennett, B., Freckelton, I. R., & Wolf, G. (2023) · Oxford University Press eBooks · doi:10.1093/oso/9780192896742.002.0010
Bennett, B., Freckelton, I. R., & Wolf, G. (2023) · Oxford University Press eBooks · doi:10.1093/oso/9780192896742.002.0004
Bennett, B., Freckelton, I. R., & Wolf, G. (2023) · Oxford University Press eBooks · doi:10.1093/oso/9780192896742.002.0003
Civil Liability, Regulation, and Accountability
Bennett, B., Freckelton, I. R., & Wolf, G. (2023) · Oxford University Press eBooks · doi:10.1093/oso/9780192896742.003.0009
Bennett, B., Freckelton, I. R., & Wolf, G. (2023) · Oxford University Press eBooks · doi:10.1093/oso/9780192896742.002.0005
COVID-19 and Workplace and Occupational Health and Safety
Bennett, B., Freckelton, I. R., & Wolf, G. (2023) · Oxford University Press eBooks · doi:10.1093/oso/9780192896742.003.0010
Development of COVID-19 Treatments and Vaccines
Bennett, B., Freckelton, I. R., & Wolf, G. (2023) · Oxford University Press eBooks · doi:10.1093/oso/9780192896742.003.0011
Yatskevich, N., Гурбанова, Э., Гуревич, Г. Л., Ованнесян, А., & Скрягина, Е. М. (2023) · Рецепт · doi:10.34883/pi.2023.26.1.005
Aguilar‐Jiménez, J. R., Pelissari, D. M., & Díaz-Quijano, F. A. (2023) · medRxiv · doi:10.1101/2023.03.07.23286916
雍, 彧. (2023) · Advances in Clinical Medicine · doi:10.12677/acm.2023.134937
Yatskevich, N., Гуревич, Г. Л., Синха, A., Альварез, Х. Л., Лахеналь, Н., Garsevanidze, E., & Скрягина, Е. М. (2023) · Рецепт · doi:10.34883/pi.2023.26.2.010
Pecho‐Silva, S., Navarro‐Solsol, A. C., Panduro‐Correa, V., Maguiña, J. L., Rabaan, A. A., Quiroz-Ramirez, L. R., Arteaga‐Livias, K., & Rodriguez-Morales, A. J. (2022) · Revista del Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjo · doi:10.35434/rcmhnaaa.2022.154.1501
New Role of D-Cycloserine: Shorten Adaptation Process and Extend Maintenance Time of Motion Sickness
Lu, Y., Chen, Z., Pan, L., Zhang, L., Xiao, S., Qi, R., Cai, Y., & Wang, J. (2023) · Pharmacology · doi:10.1159/000530575
Incidência da tuberculose no estado de Sergipe entre 2017 e 2022: Um estudo epidemiológico
de Santana, M. V. M. (2023) · Research Society and Development · doi:10.33448/rsd-v12i8.42830
Multidrug-resistant Tuberculosis and its Implication with COVID-19
Arya, J., Dahiya, S., & Chhillar, A. K. (2023) · Coronaviruses · doi:10.2174/2666796704666230822113632
Kootery, K. P., & Sarojini, S. (2023) · Biologia · doi:10.1007/s11756-023-01559-4
Tuberculosis in Children and Hearing Loss
Hatipoğlu, N., Arısoy, E. S., & Starke, J. R. (2023) · Comprehensive ENT · doi:10.1007/978-3-031-38495-0_37
Antituberculous Agents for Pediatric Mycobacterial Diseases, and Hearing Loss
Hatipoğlu, N., Arısoy, E. S., & Muñoz, F. M. (2023) · Comprehensive ENT · doi:10.1007/978-3-031-38495-0_70
Raznatovska, О. М., Yasinskyi, R. M., Shalmin, О. S., & Fedorec, A. V. (2023) · Infusion & Chemotherapy · doi:10.32902/2663-0338-2023-4-40-44
Maihemuti, M., Wu, J., Dai, Z., Maimaiti, A., & Jiang, R. (2024) · Research Square · doi:10.21203/rs.3.rs-3839737/v1
Oral and temporomandibular tuberculosis: A State-of-the-art literature review
Contreras, C., Cepeda, S. E. N., Longoria, J. A. G., Silva, J. Y. G., Coronado, J. E. A., Ruíz, M. M., Uscanga, A. D. J. Z., Ayala, Z. C. P., & Soto, J. M. S. (2024) · International Journal of Applied Dental Sciences · doi:10.22271/oral.2024.v10.i1a.1891
Iruedo, J. O., & Pather, M. K. (2024) · Research Square · doi:10.21203/rs.3.rs-3965395/v1
Du, W., Zhao, Y., Zhang, L., Che, J., Liu, Z., Li, K., & Che, N. (2022) · Figshare · doi:10.6084/m9.figshare.21622482
Du, W., Zhao, Y., Zhang, L., Che, J., Liu, Z., Li, K., & Che, N. (2022) · Figshare · doi:10.6084/m9.figshare.21622485
Amengor, C. D. K., Biniyam, P. D., Gyan, P., Kekessie, F. K., & Harley, B. K. (2024) · Research Square · doi:10.21203/rs.3.rs-4259865/v1
Wang, T., Li, M., Cai, X.-S., Qiu-sheng, C., Ze, L., Liu, T., Zhou, L., Wang, H., Feng, G., Marais, B. J., et al. (2024) · Frontiers in Microbiology · doi:10.3389/fmicb.2024.1374458 · Cited by 1
Liu, P., Gu, H., Cai, G., & Qin, Y. (2024) · Scientific Reports · doi:10.1038/s41598-024-65682-1
Tella, J. O., Ajanaku, K. O., Adekoya, J. A., Banerjee, R., Patra, C. R., Pavuluri, S., & Sreedhar, B. (2024) · International Conference on Science, Engineering and Business for Driving Sustainable Development Goals (SEB4SDG) · doi:10.1109/seb4sdg60871.2024.10630215
“INH can be used as a mono or combined therapy with either pyrazinamide, rifampicin, or both of them for the treatment of tuberculosis [12].”
BackgroundUmar, M., Basit, A., Ali, S., Iqbal, Z., & Jan, F. (2024) · Cureus · doi:10.7759/cureus.70664
Kumar, P., Toppo, A., & Pradhan, S. (2024) · MRIMS Journal of Health Sciences · doi:10.4103/mjhs.mjhs_49_24
CUIDADOS DA ENFERMAGEM PARA PACIENTES COM RESISTÊNCIA MEDICAMENTOSA NA COINFECÇÃO HIV-TB
de Oliveira, M. E., & Alves, A. P. D. P. (2024) · Revista Contemporânea · doi:10.56083/rcv4n11-166
Vadakunnel, M. J., Prakash, V., Brammacharry, U., Ramachandra, V., Palavesam, S., Muthukumar, A., Blasundaram, R. M., Sriramkumar, S. R., Pradhabane, G., Subaramani, S., et al. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.5040678
Susceptibility Test Methods: Mycobacteria, Nocardia , and Other Actinomycetes
Brown‐Elliott, B. A., Cirillo, D., Musser, K. A., & Rowlinson, M. (2023) · ClinMicroNow · doi:10.1002/9781683674849.mcm0079
Mariner-Llicer, C. (2024) · RiuNet (Universitat Politècnica de València) · doi:10.4995/thesis/10251/213332
Susceptibility Test Methods: Mycobacteria, Nocardia , and Other Actinomycetes
Brown‐Elliott, B. A., Cirillo, D., Musser, K. A., & Rowlinson, M. (2023) · ClinMicroNow · doi:10.1002/9781683670438.mcm0079
Recent Advancement of Tubercular Therapy in MDR-TB and DR-TB
Patel, F., Benade, S., Nerkar, S., Gavhade, P., Rode, S., & Giri, A. (2025) · International Journal for Research in Applied Science and Engineering Technology · doi:10.22214/ijraset.2025.68182
Chitralu, S. P. P., Dsouza, P. D., Patil, C. M., Nyamagoud, S. B., Koujalagi, V. A., & Swamy, A. H. V. (2025) · Monaldi Archives for Chest Disease · doi:10.4081/monaldi.2025.3336
MediGuide AI using Machine Learning
Pooja, R., Elugubanti, N., Mary Shiba, C., priya, K., V, Sasirekha, K., & Sabapathy, S. R. (2025) · International Conference on Machine Learning and Autonomous Systems (ICMLAS) · doi:10.1109/icmlas64557.2025.10968033
Maihemuti, M., Wu, J., Dai, Z., Maimaiti, A., & Jiang, R. (2025) · Clinical Spine Surgery A Spine Publication · doi:10.1097/bsd.0000000000001829
Sarwar, S., Sajid, M. T., Mukhtar, S., Ahmad, R., Sarwar, S., Mukhtar, M., & Atif, M. (2025) · Monaldi Archives for Chest Disease · doi:10.4081/monaldi.2025.3367 · Cited by 1
Radhakrishnan, L., Navabshan, I., LAVANYA, V. A., Jamal, S., & Ahmed, N. (2025) · In Silico Pharmacology · doi:10.1007/s40203-025-00388-4
“The first-line anti-TB drugs include rifampicin, iso - niazid, ethambutol, streptomycin and pyrazinamide, while fluoroquinolones, kanamycin and amikacin are the second line drugs (Sharma et al. 2020 ; Mirzayev et al. 2020).”
Anabila, N. A. (2025) · International Journal Of Health Science · doi:10.55606/ijhs.v5i2.5513
Spinal Tuberculosis Mimicking Metastatic Lung Cancer: A Case of Misdiagnosis
Mkrtchyan, S. (2025) · Cureus · doi:10.7759/cureus.91815
Naderifar, M., Ghaljeh, M., Sabagh, K., Amani, B., & Akbarizadeh, M. (2025) · Health Scope · doi:10.5812/healthscope-164233
Albayrak, F., Savaş, N. Y., Mutlu, M., Sayıner, Z. A., & Kısacık, B. (2025) · BMJ Case Reports · doi:10.1136/bcr-2025-265465
Sun, F., Li, Y., Zhang, Y., Cai, C., Chen, Y., Yi, H., Wu, Q., Yuan, Q., Yu, H., Lan, Y., et al. (2025) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2025.11.015
Fang, S., Jiang, J., Sun, J., & Liu, F. (2025) · European journal of medical research · doi:10.1186/s40001-025-03449-8
“Molecular diagnostic techniques, notably polymerase chain reaction (PCR), have significantly improved PTB diagnosis due to their high sensitivity, specificity, rapidity, and cost-effectiveness [7].”
New Drugs, Clinical Trials, and Innovations in Tuberculosis Treatment
Mishra, M. P. (2025) · IGI Global eBooks · doi:10.4018/979-8-3373-3446-2.ch012
Pratiwi, A., Budinugroho, A., Puspitosari, W. A., & Krairiksh, M. (2025) · Environment-Behaviour Proceedings Journal · doi:10.21834/e-bpj.v10isi35.7509
Yao, C., Guo, H., Li, Q., Zhang, X., Shang, Y., Li, T., Wang, Y., Xue, Z., Wang, L., Li, L., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16456320
Ross, J., Perumal, R., Wolf, A., Zulu, M., Guzman, K. J., Seepamore, B., Reis, K., Nyilana, H., Hlathi, S., Narasimmulu, R., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26647995
Ross, J., Perumal, R., Wolf, A., Zulu, M., Guzman, K. J., Seepamore, B., Reis, K., Nyilana, H., Hlathi, S., Narasimmulu, R., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26647992
Du, W., Zhao, Y., Zhang, L., Che, J., Liu, Z., Li, K., & 车南颖 (2022) · Figshare · doi:10.6084/m9.figshare.21622488
Wavhale, S. R., Shaikh, A. R., & Wavhale, R. (2025) · Medical Hypotheses · doi:10.1016/j.mehy.2025.111761
Arı, O., Durmaz, R., Arslantürk, A., & Vezir, S. (2026) · Acta Microbiologica et Immunologica Hungarica · doi:10.1556/030.2026.02818
Maleki, M. R. (2026) · Infection and Drug Resistance · doi:10.2147/idr.s568121 · Cited by 2
“75,76 Recent structural and biochemical studies by Batson et al have revealed a more complex mechanism: inside mycobacterial cells, DCS is phosphorylated by cellular kinases to form 3-phosphorylated D-cycloserine.”
Alvarez, S. N., & Peralta, M. I. (2025) · Journal of Medical Sciences and Interdisciplinary Research · doi:10.51847/vfpndetyjb
Ashfaq, H., Humayun, A., Naseem, M., Siddiqui, S. W., Kamal, A., Mohsin, S. N., Abdullah, M., & Sheikh, N. H. (2026) · BMC Public Health · doi:10.1186/s12889-026-26576-1
“…expert panel in 2019, reviewed the recent evidence on MDR-TB and RR-TB treatment and published new guidelines in 2020, recommending a (9 to 11 months) shorter regimen for MDR/RR-TB cases not resistant to fluoroquinolones including bedaquiline replacing injectables and all oral regimen [9].”
Wu, Q., Zhou, Y., Zhou, X., Zhou, H., Chen, J., Zou, Y., Liu, J., Zhou, T., Ouyang, Y., Zhou, G., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-8748153/v1
Dusthackeer, A., Balasubramanian, M., Rajadas, S. E., Nirmal, C. R., Elango, P., Thiruvengadam, K., Saadhali, S. A., & Shanmugam, S. (2026) · Frontiers in Microbiology · doi:10.3389/fmicb.2026.1739149
“Accurate classification of resistance is therefore critical, as misclassification can result in inappropriate regimen selection, reduced treatment eÿcacy, and amplification of resistance (Mirzayev et al., 2021).”
Advances in Clinical Features, Diagnosis and Treatment of Tuberculosis
Almas, K., Majeed, W., Almas, I., Khalid, I., Akram, F., Safdar, M., Rehman, A., & Tajammal, A. (2025) · doi:10.61748/apit.2025/08
Ndiaye, M. D. (2023) · theses.fr (ABES) · doi:10.70675/457d4bb8zd7d5z45d4z9570z844a14c5dc01 · Cited by 1
Pulmonary tuberculosis complicated by tuberculous meningitis and pulmonary embolism: A case report
Zhang, Z., Lu, X., & Duan, X. (2026) · Asian Journal of Surgery · doi:10.1016/j.asjsur.2026.03.142
Sadeghi, Z., Sharifi, M., Malekzadeh, M., Ghaedamini, S., & Hashemibeni, B. (2026) · Research in Pharmaceutical Sciences · doi:10.4103/rps.rps_247_24
“According to the World Health Organization (WHO), approximately 1.3 million women are confirmed to receive timely treatment every year (2).”
InfluentialSineke, N., Faye, L. M., Dlatu, N., Ombinda-Lemboumba, S. S., & Apalata, T. R. (2026) · Infectious Disease Reports · doi:10.3390/idr18050110
“As shown in Table 2, parameters describing TB natural history, treatment pathways and mortality were informed by published epidemiological evidence where appropriate [19–24, 27, 29].”
InfluentialDrug Repositioning: An Alternative Strategy to Tackle Multidrug-Resistant M. tuberculosis
Sharma, D., Singh, I., Verma, I. K., Ratn, A., Bisht, D., Dalal, J., & Dhakad, M. S. (2026) · Springer eBooks · doi:10.1007/978-981-92-0256-0_9
Kaminyoge, W., Simfukwe, R., Singini, M. G., Sitali, N., & Chilunga, F. P. (2026) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000005269
“5,46 Therefore, this study should be interpreted as a complementary descriptive synthesis, providing an overview of treatment effectiveness and reported adverse effects.”
Rahman, M. W., Sarker, M., Kamal, M. H. M., Khan, M. S. A., & Sume, S. J. (2024) · Kushtia Medical College Journal · doi:10.70945/kumcj.v08.i02.132
“7 The mainstay of treatment for abdominal tuberculosis remains medical management through a standardized regimen of antitubercular therapy.”
Advances in mycobacteriophage research: from lytic mechanisms to one health applications
Han, R., Shen, L., Chen, V., Tan, X., An, N., 柯东晖, Li, Y., & Zeng, J. (2026) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2026.1856292
“This environmental persistence underscores mycobacterial infections as a typical example of cross-species and cross-environmental transmission (Mirzayev et al., 2021).”
Tuberculosis in Cirrhosis: A Diagnostic and Therapeutic Challenge
Shastri, A., & Taneja, S. (2026) · Digestive Diseases and Sciences · doi:10.1007/s10620-026-10068-8
“The World Health Organization no longer uses "second-line" classification for drug-resistant TB; instead, drugs are grouped based on efficacy and safety into individualised or standardized regimens [41].”
黄润, He, Y., Yang, J., Liu, Y., Sun, Q., Ying, R., & Sha, W. (2026) · Microbiology Spectrum · doi:10.1128/spectrum.02128-25
Fadhil, M. (2026) · Indian Journal of Tuberculosis · doi:10.1016/j.ijtb.2026.07.014
Chandrashekar, C., Patel, M., Jandwa, H., Jadeja, A., & Javvaji, C. K. (2026) · Cureus · doi:10.7759/cureus.113404
“These tactics, enhanced by rapid diagnostics and incorporated into clinical workflows, constitute the foundation of effective stewardship interventions across various infectious diseases and healthcare environments [60-62].”
Shah, H., Rai, S., Patel, J., Sen, A., & Sharma, R. (2026) · Cureus · doi:10.7759/cureus.113575
“This ensured that the application could mirror the real-world diagnostic and treatment cascades, providing specific guidance for complex scenarios such as drug-resistant TB or pediatric TB management, which are often difficult to navigate using traditional paper-based guidelines [12].”
Antaria, A., Agustina, H., Ratnawati, R., Andarini, S., & Handayani, D. (2026) · PLoS ONE · doi:10.1371/journal.pone.0351836 · Cited by 1
“The WHO 2020 update on drug-resistant TB treatment guidelines endorsed all-oral regimens and specifically recommended BPaL for pre-XDR-TB and treatment-refractory MDR-TB [21].”
Nwafor, I. E., Ufoaroh, C. U., Ezeanolue, B. C., Afiadigwe, E. E., Obasikene, G., Menkiti, F. E., Nwafor, E. N., & Nduka, C. C. (2026) · Journal of the Pan African Thoracic Society · doi:10.25259/jpats_12_2026
Comparative pharmacovigilance analysis of intravenous versus oral linezolid
Zhou, Q., He, X., & Xu, X. (2026) · Medicine · doi:10.1097/md.0000000000050610
“[4] 8] In clinical practice, linezolid can be administered both orally and intravenously.”
Rodrigues, C. S., Gonçalves, L. I., Sant’Anna, C. C., Chiang, S. S., & Carvalho, A. C. C. (2026) · Respiratory Research & Clinical Practice · doi:10.36416/1806-3756/e20250341
Yi, W., Luo, F., Yi, D., Guo, J., Liu, S., Yan, Q., & Luo, H. (2026) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2026.1947704
“…drugs has declined in many settings as all-oral regimens have expanded, but their resistance markers retain regional, historical, and epidemiological relevance (Sinha et al., 2023; Mirzayev et al., 2021; Cegielski et al., 2021; Dean et al., 2022; Wang et al., 2019; Georghiou et al., 2012).”
Wang, S., Alam, M. S., Yusuf, B., Zhang, J., Lu, Z., Zhang, X., Hameed, H. M. A., Khatun, M. S., Li, C., Li, L., et al. (2026) · mLife · doi:10.1002/mlf2.70103
Akolbekova, D., & Arystanov, Z. (2026) · Indian Journal of Tuberculosis · doi:10.1016/j.ijtb.2026.09.005
Singh, G. V., Tyagi, D., Gupta, S. K., Kumar, S., & Singh, G. (2026) · Annals of the National Academy of Medical Sciences (India) · doi:10.25259/anams_45_2026
Novel and emerging anti-tubercular drugs: Reshaping the future of tuberculosis pharmacotherapy
Prasad, R., Shamim, H., Khan, W. S. M. S., Singh, A. K., & Singh, G. (2026) · Indian Journal of Tuberculosis · doi:10.1016/j.ijtb.2026.10.005
Metadata
- Authors
- Mirzayev, F., Viney, K., Linh, N. N., Gonzalez-Angulo, L., Gegia, M., Jaramillo, E., Zignol, M., & Kasaeva, T.
- Affiliations
- World Health Organization (CH)
- Corresponding author
- Mirzayev, Fuad
- Venue
- European Respiratory Journal
- Publisher
- European Respiratory Society (ERS)
- Published
- 2020-11-26
- Volume
- 57
- Issue
- 6
- Pages
- 2003300
- ISSN
- 0903-1936 (ISSN-L)
- 1399-3003
- PMC
- PMC8176349
- OpenAlex
- W3108150642
- Cited by
- 301
- References
- 23
- Citations by year
- 2026: 31 · 2025: 53 · 2024: 43 · 2023: 88 · 2022: 64 · 2021: 22
- FWCI
- 2.08
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- European Respiratory Journal (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- United States Agency for International Development
- Russian Federation
- Unitaid
- Topics
- Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
- Health Sciences › Medicine › Infectious Diseases › Infectious Diseases and Tuberculosis
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Keywords
- drug-resistant tuberculosis, multidrug-resistant tuberculosis, rifampicin-resistant tuberculosis, bedaquiline, pretomanid, linezolid, delamanid, fluoroquinolone resistance, treatment duration, WHO treatment recommendations, antimicrobial resistance
- MeSH terms
- Linezolid, Antitubercular Agents, Drug Therapy, Combination, Female, Humans, Pregnancy, World Health Organization, Tuberculosis, Multidrug-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
